TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7609861

Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 100 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Amineptine (up to 200 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2559129

Group type: EXPERIMENTAL
Intervention: Cepharanthin (Ceph.) at a dose of 1 mg/kg
Number of subjects: 45
Study: 619829

Group type: EXPERIMENTAL
Intervention: Nurse intervention to improve medication compliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 0
Study: 31730273

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 217
Study: 31394172

Group type: EXPERIMENTAL
Intervention: Intensified ART plus auranofin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intensified ART (ART + dolutegravir and maraviroc)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No intervention (continuation of first-line ART)
Number of subjects: 15
Study: 28615434

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 402

Group type: COMPARATOR
Intervention: Traditional consultation
Number of subjects: 402
Study: 25587059

Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA subtype
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Non-diffuse-trickling GA subtype
Number of subjects: 72
Study: 23979097

Group type: EXPERIMENTAL
Intervention: Environmental modifications including signs encouraging stair use, music, and art posters in stairwells.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group with no environmental modifications.
Number of subjects: 6
Study: 22145383

Group type: EXPERIMENTAL
Intervention: Early invasive treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 112
Study: 19502023

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS) patch
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 126
Study: 16838228

Group type: EXPERIMENTAL
Intervention: 3 g of tolevamer per day
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: 6 g of tolevamer per day
Number of subjects: 289

Group type: COMPARATOR
Intervention: 500 mg of vancomycin per day
Number of subjects: 289
Study: 14755206

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cold scalpel technique
Number of subjects: 33
Study: 11063152

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9205815

Group type: EXPERIMENTAL
Intervention: Propranolol (0.108 mg per kg of IBW)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Labetalol (0.99 mg per kg of IBW)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nebivolol (0.073 mg per kg of IBW)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (non-obese subjects)
Number of subjects: 18
Study: 8418273

Group type: EXPERIMENTAL
Intervention: Radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab' of IMMU-4, an anti-CEA monoclonal antibody
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radioimmunodetection (RAID)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CT
Number of subjects: 62
Study: 3763079

Group type: EXPERIMENTAL
Intervention: 2000 mL Plasma‐Lyte A
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1000 mL 5% albumin (colloid infusion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1000 mL Plasma‐Lyte A
Number of subjects: 45
Study: 30869814

Group type: EXPERIMENTAL
Intervention: BLI-bright
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LCI
Number of subjects: 10

Group type: COMPARATOR
Intervention: WLI
Number of subjects: 10
Study: 30179153

Group type: EXPERIMENTAL
Intervention: Intensive therapy (combined aspirin, clopidogrel and dipyridamole)
Number of subjects: 3096

Group type: COMPARATOR
Intervention: Guideline therapy (combined aspirin and dipyridamole, or clopidogrel alone)
Number of subjects: 3096
Study: 26940692

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 25297989

Group type: EXPERIMENTAL
Intervention: Routine TDM
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rescue TDM
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Routine TDM (with dosage recommendations adopted)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Routine TDM (median C min)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rescue TDM (median C min)
Number of subjects: 56
Study: 22686181

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia DCLC (SA-DCLC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: General anesthesia DCLC (GA-DCLC)
Number of subjects: 180
Study: 20189160

Group type: EXPERIMENTAL
Intervention: 2.2-mm clear corneal incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.65-mm clear corneal incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both incision sizes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Side port incision
Number of subjects: 60
Study: 18222450

Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate (IMN)
Number of subjects: 102

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study: 15641953

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 12860493

Group type: EXPERIMENTAL
Intervention: Adalimumab 0.25, 0.5, 1, 3, or 5 mg/kg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 60
Study: 10527826

Group type: EXPERIMENTAL
Intervention: uPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: uPAR
Number of subjects: 0
Study: 8664717

Group type: EXPERIMENTAL
Intervention: Specialist nurse visits over 12 months, minimum of six visits during the first six months.
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Specialist nurse visits for mildly disabled patients (Barthel index 15-19).
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group received no visits.
Number of subjects: 240
Study: 2051352

Group type: EXPERIMENTAL
Intervention: Threaded dowels (nine types)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nonthreaded dowels (three types)
Number of subjects: 140
Study: 6839972

Group type: EXPERIMENTAL
Intervention: Atrioventricular sequential pacemaker (group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ventricular stimulating pacemaker (group A)
Number of subjects: 16
Study: 30566758

Group type: EXPERIMENTAL
Intervention: Otelixizumab 9 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Otelixizumab 18 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Otelixizumab 27 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 26035669

Group type: EXPERIMENTAL
Intervention: Low-intensity, home-based exercise protocol led by an advanced practice nurse for 12 weeks (14-type joint exercises and walking)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study: 24960402

Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2‐6 (Arm A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg q3w for six cycles (Arm B)
Number of subjects: 30
Study: 22858630

Group type: EXPERIMENTAL
Intervention: Exercise (3 × 45 min on a bicycle ergometer at 50% of their altitude‐specific maximal workload)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 16
Study: 19324501

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Prize-based Contingency Management (prize CM)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Voucher-based Contingency Management (voucher CM)
Number of subjects: 142
Study: 17077105

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) ON
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) OFF
Number of subjects: 11
Study: 15701213

Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 1.25 mg (0.5 mg/mL) once daily for ages 2-5 years
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 2.5 mg once daily for ages 6-11 years
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 11730186

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol plus Beclomethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Baseline)
Number of subjects: 0
Study: 9475319

Group type: EXPERIMENTAL
Intervention: Early postnatal hypoglycaemia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Maternal hyperglycaemia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cord insulin-like growth factor-I or glucagon concentrations
Number of subjects: 118
Study: 7934537

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 2963522

Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400 or 600 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5, 25 or 37.5 mg once daily)
Number of subjects: 30
Study: 31609443

Group type: EXPERIMENTAL
Intervention: HFpEFLW+ (patients who developed EVLW during exercise)
Number of subjects: 61

Group type: COMPARATOR
Intervention: HFpEFLW- (patients who did not develop EVLW during exercise)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HFpEFLW+
Number of subjects: 61
Study: 27733895

Group type: EXPERIMENTAL
Intervention: Nutritional risk screening
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Swallow testing
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Proactive implementation of screening
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Overall prevalence of nutritional risk
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Initial swallow test failure
Number of subjects: 185
Study: 24617243

Group type: EXPERIMENTAL
Intervention: Rehabilitation + Massage (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rehabilitation + Acupuncture (Group B)
Number of subjects: 60
Study: 21459659

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 392
Study: 18270224

Group type: EXPERIMENTAL
Intervention: Active-LIPUS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Inactive-LIPUS (placebo)
Number of subjects: 37
Study: 16549462

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (normolipidemic patients)
Number of subjects: 9
Study: 15196519

Group type: EXPERIMENTAL
Intervention: Light touch (L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heavy touch (H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No touch (N)
Number of subjects: 20
Study: 11743267

Group type: EXPERIMENTAL
Intervention: Dopamine (3 microg./kg. per minute infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No dopamine (control group)
Number of subjects: 24
Study: 9718103

Group type: EXPERIMENTAL
Intervention: Outpatient treatment and 12-step groups
Number of subjects: 3018

Group type: COMPARATOR
Intervention: No aftercare
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Outpatient mental health treatment and 12-step group attendance
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Regular outpatient appointments
Number of subjects: 3018
Study: 7655203

Group type: EXPERIMENTAL
Intervention: Topical therapy with prednisolone 1% eye drops (Inflanefran forte) 5 times per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subconjunctival injection of 4 mg dexamethasone (Fortecortin) immediately at the end of surgery; topical therapy as in group A
Number of subjects: 30
Study: 2528941

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 47
Study: 5801346

Group type: EXPERIMENTAL
Intervention: Intraperitoneal fluid infusion with normal saline and 28 mEq of potassium chloride per litre
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intraperitoneal fluid infusion with half-strength Darrow's solution
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Premedication with promazine
Number of subjects: 91
Study: 31738680

Group type: EXPERIMENTAL
Intervention: Silicon skin pad
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tea towel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Video
Number of subjects: 32
Study: 30499374

Group type: EXPERIMENTAL
Intervention: Audio diary method
Number of subjects: 0
Study: 28657396

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone 125 mg (group MP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Isotonic saline IV (group C)
Number of subjects: 61
Study: 25386830

Group type: EXPERIMENTAL
Intervention: Capoeira and jumping exercise intervention (10-min, 3 times per week for 9 months)
Number of subjects: 188
Study: 23940225

Group type: EXPERIMENTAL
Intervention: DD AC→PG (DD doxorubicin and cyclophosphamide followed by DD paclitaxel with gemcitabine)
Number of subjects: 4894

Group type: COMPARATOR
Intervention: DD AC→P (DD doxorubicin and cyclophosphamide followed by DD paclitaxel)
Number of subjects: 4894

Group type: EXPERIMENTAL
Intervention: DD AC→PG
Number of subjects: 4894

Group type: COMPARATOR
Intervention: DD AC→P
Number of subjects: 4894

Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 4894

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 4894
Study: 21555324

Group type: EXPERIMENTAL
Intervention: OptiVol fluid status monitoring with CareAlert notification
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard clinical assessment (regular care)
Number of subjects: 1000
Study: 19421839

Group type: EXPERIMENTAL
Intervention: Floating electrodes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fixed electrodes
Number of subjects: 42
Study: 16453248

Group type: EXPERIMENTAL
Intervention: Low dose of Jarsin (extract of St John's wort)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose of Jarsin (extract of St John's wort)
Number of subjects: 20
Study: 15278047

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg per day for 7 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Omeprazole 20 mg per day for 28 days
Number of subjects: 69
Study: 11802492

Group type: EXPERIMENTAL
Intervention: Family Therapy Enactment Rating Scale (FTERS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Revised FTERS
Number of subjects: 27
Study: 9413749

Group type: COMPARATOR
Intervention: Ergometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endurance exercise at 60% of maximal work intensity
Number of subjects: 0
Study: 8449588

Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy (800 mg on day 1, then 400 mg on days 2, 3, 5, 12, and 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy (800 mg initially, then 400 mg at weekly intervals)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy
Number of subjects: 40
Study: 3300316

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg three times a day
Number of subjects: 392

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg) twice daily
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Norfloxacin (both doses)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Norfloxacin (lower dose)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Norfloxacin (higher dose)
Number of subjects: 392
Study: 30021584

Group type: EXPERIMENTAL
Intervention: Flat flexible shoes
Number of subjects: 164

Group type: COMPARATOR
Intervention: Stable supportive shoes
Number of subjects: 164
Study: 28601972

Group type: EXPERIMENTAL
Intervention: TAK-228 8-mg QDx3d QW plus paclitaxel 80 mg/m2
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TAK-228 10-mg QDx3d QW plus paclitaxel 80 mg/m2
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TAK-228 with/without trastuzumab
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study: 25910632

Group type: EXPERIMENTAL
Intervention: PCT-guided care and viral PCR testing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 24192332

Group type: EXPERIMENTAL
Intervention: Zidovudine-containing triple-ARV prophylaxis continued during breastfeeding up to 6 months
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour
Number of subjects: 1070
Study: 21932025

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) plus regional hyperthermia (HT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 68
Study: 18176972

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d plus 5-ASA 2 g/d daily for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5-ASA 2 g/d alone for 4 weeks
Number of subjects: 42
Study: 16646033

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and then every 6 weeks thereafter
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 12683261

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a combination of AA (Arachidonic Acid) and DHA (Docosahexaenoic Acid) and antioxidants (vitamins E and C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotic treatment
Number of subjects: 0
Study: 10979928

Group type: EXPERIMENTAL
Intervention: PMP-resistant Staphylococcus aureus strains
Number of subjects: 58

Group type: COMPARATOR
Intervention: PMP-susceptible Staphylococcus aureus strains
Number of subjects: 58
Study: 8634416

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HIDAC-3-7) 3 g/m2 12 hourly on days 1, 3, 5, and 7 for 8 doses, with daunorubicin 50 mg/m2 days 1 to 3, etoposide 75 mg/m2 days 1 to 7.
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard dose cytarabine (7-3-7) 100 mg/m2 continuous intravenous infusion for 7 days, with daunorubicin and etoposide at the same dose and schedule as HIDAC-3-7.
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: HIDAC-3-7
Number of subjects: 301

Group type: COMPARATOR
Intervention: 7-3-7
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Consolidation treatment (5-2-5)
Number of subjects: 301
Study: 1458044

Group type: EXPERIMENTAL
Intervention: Processes of change in smoking cessation for cardiac patients
Number of subjects: 213

Group type: COMPARATOR
Intervention: Processes of change in smoking cessation for nonmedical smokers
Number of subjects: 213
Study: 6202571

Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily, 200 mg every 8 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 26
Study: 30777584

Group type: EXPERIMENTAL
Intervention: Medication adherence (assessed by a blind clinician)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Medication adherence (assessed by a nonblind clinician)
Number of subjects: 34
Study: 29091342

Group type: EXPERIMENTAL
Intervention: LDV/SOF for 12 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LDV/SOF + RBV for 12 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LDV/SOF for 24 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LDV/SOF + RBV for 12 weeks (A5348 study)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: LDV/SOF for 24 weeks (A5348 study)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Serious AEs
Number of subjects: 89
Study: 26856211

Group type: EXPERIMENTAL
Intervention: Usual stroke unit diagnostic procedures plus standardized and centrally analyzed Holter ECG recording for up to 7 days in hospital
Number of subjects: 3470

Group type: COMPARATOR
Intervention: Usual stroke unit diagnostic procedures for detection of AF
Number of subjects: 3470
Study: 24530788

Group type: EXPERIMENTAL
Intervention: Beer (30 g alcohol/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer (equivalent polyphenols)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gin (30 g alcohol/d)
Number of subjects: 33
Study: 22550117

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-7 (rhIL-7) at a dose of 20 µg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20403021

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heroin
Number of subjects: 12
Study: 17852016

Group type: EXPERIMENTAL
Intervention: Sequential trial design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical trial design
Number of subjects: 0
Study: 16119665

Group type: EXPERIMENTAL
Intervention: Thoracosurgical patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: General surgical patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-care ability evaluation
Number of subjects: 100
Study: 12105117

Group type: EXPERIMENTAL
Intervention: Repeated administration of MDMA (3,4-methylenedioxymethamphetamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA in poor metabolizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recreational MDMA use over a 2-year observation period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal values of lymphocyte subsets in MDMA users
Number of subjects: 0
Study: 11816697

Group type: EXPERIMENTAL
Intervention: IL1RN-VNTR genotype
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control group (age- and smoking-matched)
Number of subjects: 770
Study: 9260077

Group type: EXPERIMENTAL
Intervention: Caffeinated cola (33 mg/8 oz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo cola (noncaffeinated)
Number of subjects: 24